The Committee for Medicinal Products for Human Use (CHMP) decided that Fosavance’ s benefits are greater than its risks for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D insufficiency.
2/ 3 οστεοπόρωσης σε ασθενείς που διατρέχουν κίνδυνο ανεπάρκειας βιταμίνης D.